Last reviewed · How we verify

NCT06710652

Efficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Insomnia with Subjective Cognitive Decline

Not yet recruiting NA Last updated 29 November 2024
What this trial tests

NA trial testing rTMS in Insomnia Chronic in 66 participants. Not yet recruiting.

Timeline
1 January 2025
Primary endpoint
30 June 2026
30 June 2026

Quick facts

Lead sponsorFujian Medical University Union Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment66
Start date1 January 2025
Primary completion30 June 2026
Estimated completion30 June 2026

Drugs / interventions tested

Conditions studied

Sponsor

Fujian Medical University Union Hospital

Who can join

Adults 30 to 80, any sex, with Insomnia Chronic or Subjective Cognitive Decline (SCD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Insomnia is the most common form of sleep disorder, and subjective cognitive decline (SCD) in patients with insomnia may be an ultra-early manifestation of AD. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising tool for the treatment of insomnia by modulating neural excitability and inducing plasticity. However, there is a lack of studies on rTMS treatment of cognitive impairment associated with insomnia. The efficacy and safety of rTMS for cognitive impairment in insomnia patients with SCD will be assessed by a randomized controlled trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of rTMS

Trials testing the same drug.

Other recruiting trials for Insomnia Chronic

Currently open trials in the same condition.

Other Fujian Medical University Union Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06710652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing